权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Omics Analyses of HIV and Substance Use Disorder

HIV 和药物滥用障碍的组学分析

基本信息

批准号：
10213682
负责人：
Vez REPUNTE-CANONIGO
金额：
$ 85.62万
依托单位：
SCRIPPS RESEARCH INSTITUTE, THE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-30 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10213682
关键词：
Aging Alzheimer&apos s Disease Area Automobile Driving Behavioral Biochemical Clinical Data Disease Progression Dissection Drug abuse Environment Gene Expression Gene Expression Profiling Genes Grant HIV HIV-associated neurocognitive disorder Human Huntington Disease In Vitro Individual Inflammation Injury Integration Host Factors Literature Lymphocyte Mass Spectrum Analysis Messenger RNA Methods Methylation MicroRNAs Microglia Modification Molecular Morphology National NeuroAids Tissue Consortium Nerve Degeneration Neuraxis Neurodegenerative Disorders Neurons Neuropsychology Nitric Oxide Oxidative Stress Parkinson Disease Pathogenesis Pathogenicity Pathway interactions Patients Play Post-Translational Protein Processing Production Protein S Proteins Proteomics RNA RNA Processing RNA methylation Rattus Recording of previous events Regulation Regulator Genes Role Sampling Signaling Molecule Substance Use Disorder Substance abuse problem System Systems Biology Testing Transcript Transgenic Organisms Ursidae Family Validation Virus behavioral phenotyping cell type comorbidity disease classification druggable target effective therapy epitranscriptomics frontal lobe improved in vivo miRNA expression profiling multidisciplinary neuroAIDS new therapeutic target novel novel therapeutics oxidative damage programs public health relevance reactivation from latency stimulant abuse transcriptome sequencing transcriptomics virology

项目摘要

Summary In order to generate new mechanistic hypotheses on neuroHIV pathogenesis and disease progression to identify novel therapeutic targets to improve neuropsychological functioning in people with HIV, substance abuse comorbidity and neurodegenerative diseases, this proposal will utilize convergent state-of-the-art Omics strategies including transcriptomic, epitranscriptomic and proteomics. Specifically, we will carry out gene expression profiles by RNA-Seq from the frontal cortex of HIV+ patients and controls representative of cART era clinical presentations with and without histories of dependent substance abuse from samples of the National NeuroAIDS Tissue Consortium (NNTC). We will bring to bear a systems biology framework to generate mechanistic hypotheses that in preliminary studies allowed us to identify candidate drivers of gene expression changes associated with neuroHIV and neurodegenerative diseases including Alzheimer’s and Huntington’s diseases. The scientific literature together with our preliminary results, indicate that N6- methyladenosine (m6A) RNA methylation represents an additional layer of host gene expression of great potential pathogenic significance in both neuroHIV and Alzheimer’s disease. In particular, preliminary results indicate that HIV induces altered m6A methylation of transcripts involved in pathways related to synaptodendritic injury and neurodegeneration, inflammation and RNA processing, thus m6A RNA methylation profiling will also be carried out. Excessive production of the signaling molecule nitric oxide (NO) leads to protein S-nitrosylation, a posttranslational modification associated with aging, neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases, and neuroHIV. Our preliminary data show convergent results from analyses of gene expression and S-nitrosoproteomics. Therefore, we will integrate the transcriptomics with Mass Spectrometry (MS) proteomic analysis of the S-nitrosoproteome. In summary, these studies will apply an integrated Omics approach including little understood and emerging aspects of host-HIV regulatory interactions, such as RNA-methylation and protein nitrosylation in a systems biology framework to generate mechanistic hypotheses that will be tested in the second part of the grant to identify novel therapeutic concepts to improve neuropsychological functioning in people with HIV, substance abuse comorbidity and neurodegenerative diseases.

总结